Sickle Cell Disease Drugs Market to Reach USD 2.45 Billion by 2032

Sickle Cell Disease Drugs Market to Reach USD 2.45 Billion by 2032 as Gene Therapy, Wider Diagnosis and Persistent VOC Burden Reshape Treatment

The Global Sickle Cell Disease Drugs Market was valued at approximately USD 1.15 billion in 2025 and is projected to reach USD 2.45 billion by 2032, expanding at a CAGR of approximately 11.4% during 2026–2032. Growth is being supported by rising diagnosis, broader use of disease-modifying therapies, recurrent vaso-occlusive crisis burden, pediatric treatment expansion and the commercial rollout of gene therapies.

North America accounted for an estimated USD 470 million in 2025, with the United States contributing approximately USD 440 million. The region represents a much larger share of market revenue than of global SCD prevalence because branded therapy utilization, insurance coverage, specialist access and adoption of advanced treatments are substantially higher.

Large Disease Burden Still Exceeds the Treated Population

Sickle cell disease remains one of the world's most significant inherited blood disorders. WHO estimated that approximately 7.74 million people were living with SCD globally in 2021, with around 515,000 affected births annually. Nearly 80% of cases are concentrated in sub-Saharan Africa, where access to newborn screening, hematology care and long-term treatment remains uneven.

The global prevalent population was estimated at approximately 8.2 million patients in 2025, while around 4.75 million were diagnosed or clinically identified. Approximately 3.7 million patients were considered broadly eligible for disease-modifying therapy, but only around 1.32 million were receiving active treatment.

This treatment gap remains one of the strongest sources of future market expansion. Diagnosis alone does not create commercial demand; patients must remain connected to care, receive disease-modifying therapy and continue treatment long enough to achieve clinical benefit.

Recurrent VOCs Define the Highest-Need Patient Group

Vaso-occlusive crises remain a major clinical and economic burden. Recurrent VOCs are associated with severe pain, emergency-department utilization, hospitalization, transfusion, acute chest syndrome, stroke and progressive organ damage.

Approximately 1.4–1.7 million diagnosed patients globally were estimated to have moderate-to-severe disease or recurrent VOCs in 2025. These patients represent the most important target population for treatment intensification, newer branded therapies and advanced treatments.

Recent U.S. data in frequently transfused patients reported approximately 4.0 VOCs, 8.3 red-cell transfusions and 2.3 inpatient admissions per patient annually, with mean healthcare costs reaching approximately USD 106,123 per patient per year. In recurrent-VOC populations, annual healthcare expenditure has also been reported near USD 67,282 per patient.

The high cost of repeated complications strengthens the value of therapies that can reduce crisis frequency, hospitalization and cumulative organ damage.

Hydroxyurea Retains the Largest Treatment Volume

Hydroxyurea remained the largest treatment segment in 2025, accounting for approximately 1.15–1.20 million patient-years, or close to 90% of global disease-modifying treatment volume.

Its broad clinical use and relatively low cost support continued leadership by patient numbers, but treatment penetration remains uneven. SickleInAfrica registry data reported hydroxyurea utilization of approximately 21% in Ghana, 12% in Nigeria and 6% in Tanzania, showing how access remains limited in several high-burden countries.

Persistence is another weakness. U.S. claims data have shown a mean medication-possession ratio of 0.52, while only 22.3% of patients achieved adherence of at least 80% and 58.9% discontinued within 12 months under the study definition.

These gaps leave significant room for treatment expansion and for therapies that can address persistent VOCs or inadequate disease control.

Gene Therapy Changes Market Value Despite Low Patient Volume

Gene therapy has become the highest-value treatment segment despite treating only a small number of patients.

Casgevy is priced at approximately USD 2.2 million per patient, while Lyfgenia carries a list price of approximately USD 3.1 million. These therapies are used in highly selected patients because treatment requires stem-cell collection, conditioning, specialist centers and long-term monitoring.

Vertex reported USD 116 million in Casgevy revenue during 2025 from 64 infusions across SCD and transfusion-dependent beta-thalassemia, while 147 patients underwent first cell collection. The company has identified more than 60,000 eligible SCD and TDT patients across approved markets, including approximately 37,000 in North America and Europe and more than 23,000 in the Middle East.

Casgevy's U.S. label expansion in July 2026 to patients aged two years and older with recurrent VOCs widened the potential treatment population and brought gene therapy further into pediatric care.

U.S. Market Remains the Commercial Center

The United States accounts for approximately 100,000 people with SCD, yet generates a disproportionately large share of global drug revenue.

The U.S. Sickle Cell Disease Drugs Market was estimated at approximately USD 440 million in 2025, supported by high diagnosis rates, branded drug use, Medicaid and commercial insurance coverage, and early gene-therapy uptake.

The U.S. market is also economically important because SCD creates significant lifetime healthcare expenditure. NIH-supported research estimated average insurer-paid lifetime costs of approximately USD 1.7 million per patient, while commercially insured patients aged 64 years or younger incur approximately USD 44,000 in lifetime out-of-pocket medical costs.

Treatment Penetration Will Drive the Next Phase of Growth

Global disease-modifying treatment volume is projected to increase from approximately 1.3 million patient-years in 2025 to around 2.0–2.1 million by 2032.

The diagnosed SCD population is expected to reach approximately 6.2 million by 2032, while the treated population could increase to around 2.05 million. Treatment penetration among diagnosed patients is expected to rise from approximately 28% in 2025 to around 33% by 2032.

Hydroxyurea will remain the leading treatment by patient volume, while gene therapies and newer disease-modifying drugs are expected to capture a growing share of market revenue.

By 2032, gene therapies could generate approximately USD 750–850 million annually, while next-generation disease-modifying therapies could contribute another USD 450–550 million if late-stage programs translate into successful approvals and adoption.

Market opportunity - millions of patients remain diagnosed but undertreated, while a smaller high-severity group continues to experience recurrent VOCs despite available care. Growth will depend on converting more of that population into sustained treatment, while improving access to higher-value therapies for patients with the greatest clinical need.